RZLT
NASD Rezolute, Inc.$4.50 ↓ -0.14 (-3.02%) Trading Down from the previous close of $4.64
- YTD change
- +90.68%
- vs 20-day SMA
- +9.30%
- vs 200-day SMA
- +19.92%
Price ranges
Price & Performance
+0.99 (+27.12%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 78.7% away from all-time highs of $21.11
- RZLT is up 91% since the beginning of the year
- RZLT is down 49% over the past 12 months
- RZLT is up 8% over the past 1 month
- 18% of all RZLT investors are betting against RZLT
RZLT reads neutral: price sits above both the 20- and 200-day averages, the 12-month move is -47.5%.
- Previous minute
- +$0.00
- Last hour
- -$0.08
- Last 5 days
- +10.57%
- vs 8-day SMA
- +5.94%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Rezolute, Inc. operates as a biopharmaceutical company, which engages in the development of drug therapies for patients with metabolic and orphan diseases. The firm's antibody therapy, ersodetug, is designed to treat all forms of hyperinsulinism. The company was founded by Nevan Charles Elam, Ho Young Huh, and Sankaram Mantripragada in March 2010 and is headquartered in Redwood City, CA.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.